Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

C. N. Sternberg^*, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe, Christine de Balincourt, Steven Deleu, Jérôme Rapion, A. T. Van Oosterom, Th M. de Reijke, M. De Santis, A. Verbaeys, F. RingeisenJ. Bellmunt, P. Albers, F. Calais-da-SilvaShow 3 othersShow less